These 3 biotech shares have gone gangbusters across the past 12 months.
The post These 3 ASX biotech shares are all up at least 120% in a year appeared first on The Motley Fool Australia. –
Let’s have a look at the share price performance and recent news of all 3 ASX shares.
Little Green Pharma
At the time of writing, shares in this cannabis manufacturing and distribution company have climbed 121.1% over the course of 1 year. Little Green Pharma shares are also 15.33% up on the previous 5 days and 17.91% on the previous month.
Over the year-to-date, the company’s shares have posted a return of 41%, having come off a high of 94 cents on 4 February 2021.
Over the previous 6 months, the company has reported 2 major announcements, including a firm purchase order from Denmark company Demecan for 9,000 units of flower, and signing an exclusive distribution deal with leading Polish pharmaceutical group Pelion SA.
The Anteotech share price has climbed 159% this year-to-date, however is 1.72% down at the time of writing.
Over the previous 5 days, Anteotech shares have gained 26.67%, giving the company a market capitalisation of around $556 million. Shares are trading off their 52-week high of 49.5 cents, but are above the 52-week low of 2 cents.
Over the year-to-date, the company has procured a specified manufacturing line in Brisbane as part of its EuGeni Test Strip Manufacturing Strategy, forming part of a “decentralised and diversified global manufacturing approach”.
This technology provides rapid screening and identification of COVID-19 using a nasal sample. The company expects an additional capacity of 12 million strips per annum as a result of the new manufacturing line.
The Imugene share price has surged by 277% year-to-date, recently down from a high of 49 cents, coming in today at 38 cents at the time of writing.
The immuno-oncology company is up 4.05% intraday, and has gained 10% over the previous 5 days. Imugene’s market capitalisation has now reached $1.8 billion, but it has experienced a 1-month drop of 17% from the previous month.
Over the previous 6 months, the company has presented a series of positive data on clinical trial outcomes. Back in April 2021, the company released positive headline results for its phase 2 gastric cancer clinical trial.
Furthermore, on 18 May 2021, the company also announced the commencement of a phase 1 clinical trial in 2022 to expand on Imugene’s expertise in oncolytic virus and cell therapy technology, for investigation in therapy for solid tumours.
These 3 ASX biotech shares have each outperformed the broader Australian index this year, posting returns above the S&P/ASX 200 Index (ASX: XJO)’s 11% year-to-date.
The post These 3 ASX biotech shares are all up at least 120% in a year appeared first on The Motley Fool Australia.
Wondering where you should invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.
*Returns as of May 24th 2021
Why the Little Green Pharma (ASX:LGP) share price fired up 8% today
NAB and Zip were among the most traded ASX shares last week
Here’s why the Little Green Pharma (ASX:LGP) share price is down 5%
The Imugene (ASX:IMU) share price has fallen 14% in the last 5 days
These 3 ASX 200 shares are the most actively traded today
The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.